28. Oxervate

close-up of child's green eye
As an eye drop, Oxervate is the first application of a human NGF as a drug and the first topical biologic approved in ophthalmology. (Rudy and Peter Skitterians)

Active ingredient: cenegermin-bkbj
Disease: neurotrophic keratitis
Peak sales estimate: N/A
Approved: Aug. 22
Company: Dompé 

The scoop: With its FDA approval, the eye drop Oxervate from Italian drugmaker Dompé became the first treatment approved for NK, a degenerative disease that triggers a loss of corneal sensation. The condition affects fewer than 65,000 people in the U.S. each year but can result in blindness if untreated.

Oxervate is a recombinant human nerve growth factor (NGF) that resembles the human body’s natural NGF and works on corneal epithelial cells to stimulate their recovery. As an eye drop, Oxervate is the first application of a human NGF as a drug and the first topical biologic approved in ophthalmology. Before the orphan drug was approved, available treatments were either palliative or, in the case of surgeries, invasive. It will be launched in 2019. — Eric Palmer 

28. Oxervate

Suggested Articles

With a new research team, outlook and more than a little help from the tech world, GSK has been quietly going about shoring up its pipeline.

The World Health Organization has called out Big Pharma for its dearth of antibiotic innovation amid a growing threat of antimicrobial resistance.

The trial hit its primary endpoint by the time of an interim analysis, enabling Chi-Med to stop the study and start work on a filing for approval.